<DOC>
	<DOCNO>NCT01111539</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind study design assess efficacy , safety tolerability oral Aripiprazole/Escitalopram combination therapy subject MDD demonstrate incomplete response prospective trial Escitalopram , report treatment history current MDD episode inadequate response least one three adequate trial approve antidepressant Escitalopram . An inadequate response define less 50 % reduction depressive symptom severity assess subject 's self-report Massachusetts General Hospital Antidepressant Treatment Response Questionnaire ( ATRQ ) evaluate investigator part subject 's medical psychiatric history . An adequate trial define antidepressant treatment least 6 week duration ( least 3 week combination treatment ) approve dose specify ATRQ .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Tolerability Oral Aripiprazole/Escitalopram Combination Therapy Patients With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description>The study organize follow : - Screening Phase - Single-blind Prospective Treatment Phase - Single-blind Continuation Phase ( Responder ) Double-blind Randomization Phase ( non-Responder ) - 30 day Post Treatment Follow-up Assigned Interventions : - Escitalopram monotherapy - Aripiprazole/Escitalopram combination therapy - Aripiprazole monotherapy</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Subjects current diagnosis major depressive episode . The current depressive episode must ≥ 8 week duration Subjects willing discontinue prohibit psychotropic medication start time signing inform consent study period Subjects HAMD17 Total Score ≥ 18 Baseline Visit Prospective Treatment Phase Lack prior treatment antidepressant current depressive episode Subjects report treatment adjunctive monotherapy antipsychotic treatment current depressive episode . Subjects experience hallucination , delusion psychotic symptomatology current depressive episode Subjects epilepsy significant history seizure disorder Subjects clinically significant current diagnosis borderline , antisocial , paranoid , schizoid , schizotypal histrionic personality disorder Subjects receive electroconvulsive therapy ( ECT ) last 10 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
</DOC>